The stock of VBI Vaccines Inc. (NASDAQ:VBIV) is now priced at $3.65 and the shares are -0.25 points down or -6.41% lower compared to its previous closing price of $3.9. The stock had 4.727 million contracts set over the past session. VBIV shares’ daily volume is compared to its average trading volume at 12.394 million shares. However, it has a float of 151 million and although its performance was 0.27% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the VBIV share price recently placing at $3.58 to $3.9.
The shorts are climbing into the VBI Vaccines Inc. stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the VBIV shares have risen. Short interest in the stock represents just 8.14% of its float, but the volume has raised by 1542588. The volume of shorted shares rised to 12.284 million from 10.741 million shares over the last two weeks. The average intraday trading volume has been 16.203 million shares, which means that days to cover moved to roughly 1.
In the last trading session, VBI Vaccines Inc. (NASDAQ:VBIV) raised by $0.01 over the week and lost -$1.49 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $6.93. The stock recorded its established 52-week high on 07/20/20.
Since 09/30/19, the stock has traded to a low of $0.47 at 684.1%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge.
Looking at current readings, VBI Vaccines Inc.’s two-week RSI is 45.61. This suggests that the stock is neutral at the moment and that VBIV shares’ price movement remains stable. The stochastic readings are equally revealing at 24.97% meaning the VBIV share price is currently in overbought territory.
The technical chart shows that the VBIV stock will likely settle at between $3.84 and $4.03 per share. However, if the stock dips below $3.52, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $3.39.
Currently, the stock is trading in the green of MACD, with a reading of 0.01. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned VBIV a rating of Outperform in their intiating review released on January 16. Canaccord Genuity analysts see the stock as a Buy with a target price of $10 in a flash note released to investors on November 01 initiating covering the stock. Laidlaw analysts see the stock as Buy when the analysts initiated the share price coverage on October 10, placing it at $6.
The average rating for the VBIV equity is 1.5 and is currently gathering a bullish momentum. Of 4 analysts tracking VBI Vaccines Inc. polled by Reuters, 0 rated VBIV as a hold. The remaining 4 analysts were split evenly. However, the split wasn’t equal as a majority (4) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Zacks Consensus Estimate forecasts that the current-quarter revenues for VBI Vaccines Inc. (NASDAQ:VBIV) will increase by about 8.7%, which will see them reach $200 million. The company’s full-year revenues are, however, expected to increase by about 4.05%, up from $865 million to $900 million. VBIV’s expected adjusted earnings should drop almost -8.33% to end up at -$0.22 per share, while for the fiscal year, analysts project the company’s earnings to grow by about 0% to record -$0.88/share.